Rabbit hemorrhagic disease virus (RHDV), the causative agent of a highly contagious disease in wild and domestic rabbits, was first described in China in 1984 (12) . The disease was reported in Korea a year after and spread throughout Europe during the years 1987 to 1989 (19) . Infected rabbits usually died within 48 to 72 h of necrotizing hepatitis and hemorrhages, but, surprisingly, animals less than 2 months old remained unaffected (32) . The disease is responsible for great economic losses in rabbit production, which has been rapidly developing since 1980 (19) . Recently characterized as a member of the Caliciviridae family (21, 24) , the virion is 40 nm in diameter and shows a typical structured surface of regularly arranged cup-shaped depressions (21, 29) . The genome, a 7.5-kb single-stranded positive RNA, shows substantial base homology with other calicivirus genomes, but its organization differs, as only two open reading frames (ORFs) can be detected on the RHDV genome, whereas the other calicivirus genomes contain three ORFs (9, 17, 20, 25) . Together with the full-length genomic RNA, a 2.4-kb subgenomic RNA is found in the virion (17, 18, 21) . In RHDV, ORF1 extends from nucleotide 10 to nucleotide 7042, coding for a polyprotein that is cleaved into nonstructural proteins and the capsid protein VP60, which in the other caliciviruses is encoded by a distinct ORF (17, 25) . The N-terminal part of the polyprotein was found to contain consensus motifs delineated for the active sites of 2C-like helicase, 3C-like protease, and 3D-like polymerase of picornaviruses. In RHDV, the second ORF overlaps the first one by 17 nucleotides and codes for a yet-uncharacterized 12-kDa protein (18, 24) . The in vitro translation of the subgenomic RNA showed it could code for VP60, but no detectable expression of ORF2 protein was reported (4). It still remains unclear whether VP60 is encoded by the 2.4-kb subgenomic RNA or cleaved from the polyprotein (ORF1) during the viral cycle (4, 25) . The viral capsid seems to result from the multimerization of 180 copies of a single VP60 protein (27) , which therefore appears to be a good candidate for the elicitation of a protective response (24) . Both active immunization with VP60 alone and passive immunization by injection of antisera containing anti-VP60 antibodies were reported to afford protection against a viral challenge (24). However, because of the lack of a cell culture system allowing viral replication, the antigen for vaccine preparation is still extracted from livers of infected animals (2). The production of recombinant VP60 would both obviate the need to handle infectious material for vaccine preparation and be of great interest for studying VP60 oligomerization.
Recently we have cloned and sequenced the full-length genome of an RHDV isolate collected from a wild rabbit in France (25) . The VP60 gene was cloned under the control of the baculovirus polyhedrin promoter. The recombinant protein self-assembled to form viruslike particles (VLPs) that could easily be purified from the supernatant of infected Sf9 cells. The ability of these particles to protect animals was also tested.
Production and purification of recombinant VP60 particles. Two different constructions of recombinant baculoviruses expressing the VP60 gene were made. Inserts G3 and G4 were obtained by PCR with pUG 5.151 (25) (Fig. 1) kinetics of recombinant VP60 production in the supernatant of infected cells (Fig. 2) . The which were similar in size and appearance to the authentic RHDV, could be observed by electron microscopy (Fig. 3) . The majority of these particles appeared to be electron dense (Fig. 3B) . However, the lack of a major form of nucleic acid was deduced both from the buoyant density measurements, which were 1.31 g/cm3 for the VLPs versus 1.36 g/cm3 for the virus, and from the A26c/A28O ratio of the VLPs, which was found to be 1.1 instead of 1.44 for the virus preparation (24 (1, 11) . The anti-RHDV polyclonal serum was used at a 1/1,000 dilution, and MAb E3 was used at a 1/100 dilution. The polyclonal serum (Fig. 4) and MAb E3 (data not shown) recognized the same proteins both in RHDV and in VLP samples. The 60,000-molecular-weight protein (60K protein) corresponding to the monomer form of the capsid protein was immunodetected in both samples (Fig. 4A) . In the VLP sample, a minor band migrating close to the recombinant VP60 was also consistently detected (Fig. 4) . A similar result has been described for the core protein of hepatitis B virus (HBV) expressed in the baculovirus system (3). In the latter case, the minor band was found to be a polyhedrin-HBV core fusion protein which was initiated at the AUU mutated polyhedrin gene start codon of pVL941 (3, 14) . The AUG of the RHDV capsid gene is also in frame, 35 expression of a fusion protein with an Mr of 62,000. Under reducing conditions, two proteins of 36 and 26 kDa were also revealed in the RHDV sample, whereas a 40-kDa product was detected in the VLP sample (Fig. 4) . The 36-and 26-kDa proteins have already been described for an RHDV purified sample (17, 26) , and proteins with similar Mrs, 40,000 for FCV (5) Western blot analysis of the VP60 recombinant particles. VLPs present in the supernatant of Bac G3.12-infected cells were purified in a self-forming CsCl gradient. Recombinant VP60 protein and purified RHDV were solubilized at 100°C, either in the presence (A) or in the absence (B) of reducing agent (2-mercaptoethanol), electrophoresed on a 0.1% sodium dodecyl sulfate-10% polyacrylamide gel, and blotted onto a nitrocellulose membrane. Viral proteins were detected with an anti-RHDV polyclonal antiserum and revealed with an anti-rabbit immunoglobulin G alkaline phosphatase conjugate. Numbers indicate molecular weight (in thousands).
MAbs, is a degradation or a cleavage product of VP60 is still under investigation (Fig. 4A) .
A 120-kDa protein, a possible dimer of VP60, was revealed in RHDV and VLP samples when they were boiled and dissociated under nonreducing conditions (Fig. 4B) . Analysis of two VP60 amino acid sequences shows the existence of only one cysteine conserved at position 274, through which a disulfide bond maintaining the dimer could occur (17, 25) . Furthermore, under nonreducing conditions, a 100-kDa protein, which could result from the association of the 60-kDa and the 40-kDa proteins by disulfide bond if the latter is a cleavage product of VP60 containing the cysteine residue, was revealed only in the VLP sample. Vaccination of rabbits with the recombinant VP60. To investigate the immunogenicity of the recombinant protein, two groups (Gi and G2) of 10 specific-pathogen-free rabbits were vaccinated with 100 ,ug of purified VLPs produced with Bac G3.12. The VLPs were emulsified in Freund's complete adjuvant and injected intramuscularly either 15 (Gl) or 5 (G2) days before a challenge of 1,000 50% lethal doses. All rabbits that were vaccinated 15 days before challenge survived and progressively developed high anti-VP60 antibody titers as measured in a direct ELISA. In this assay, the viral antigen (10 ,ug/ml) was bound to the solid phase by incubation for 16 h at room temperature in PIPES [piperazine-N-N'-bis(2-ethanesulfonic acid)] buffer (50 mM, pH 6.4) containing 150 mM NaCl. The subsequent steps (blocking of unreacted sites, incubation with serum dilutions and anti-immunoglobulin G conjugates) were adapted from an ELISA developed in our laboratory (30) . The mean titers increased from 300 at 10 days after vaccination to 3,000 on the day of challenge (Fig. 5) . In the second group of rabbits (G2), which received the vaccine only 5 days before challenge, one rabbit died with clinical and anatomopathological signs of RHD 24 h after challenge. RHDV could be recovered from the liver of this animal, which, interestingly, was the only one of the 10 which had an antibody titer of <20. The nine other rabbits had anti-VP60 antibody titers ranging between 35 and 125 on the day of the challenge. No (A and B) ; anti-RHDV antibodies were titrated in an ELISA for which purified RHDV was used to coat the plate. The bars labeled a, b, c, and d correspond to four control groups of five rabbits. Rabbits in group a were not inoculated, those in groups b and c were inoculated 15 days before challenge, with wild baculovirus and FCA, respectively (A), and animals in group d received FCA 5 days before challenge (B). Solid vertical bars correspond to the sera from dead rabbits with titers below 20. days after challenge. In contrast, all animals belonging to the three control groups (five rabbits per group, four control groups) that received either wild baculovirus (15 days before challenge) or Freund's complete adjuvant alone (5 or 15 days before challenge) or were left untouched died between 24 and 48 h after challenge and had anti-VP60 titers of <20. RHDV could be detected in all liver homogenates from these animals.
Until now, the commercially available vaccines against RHDV have been produced from livers of infected rabbits. The baculovirus Sf9 cell expression system allows high-level production of recombinant proteins which have been proven to be potent antigens for vaccination purposes (13, 28, 31) . Injection of VLPs was able to protect rabbits against a virulent RHDV challenge under the conditions used for vaccine testing in France. Furthermore, our findings that 9 of 10 rabbits vaccinated 5 days before challenge were protected against RHDV and that the one rabbit which did not survive died of the disease were consistent with the observations that anti-RHDV protective immunity is rapidly established in infected domestic-rabbit colonies (2) . The anti-VP60 seroconversion, as measured by ELISA, was similar to the one observed when anti-RHDV antibodies were titrated in a hemagglutination inhibition assay, which revealed antibody production between the third and seventh days after vaccination with inactivated virus (2). In our experiments, anti-VP60 antibodies could be detected as early as 5 days after the vaccination and the titers progressively increased over a 15-day period. Because the once vaccinated animal which died of RHD did not develop any antibody response, we assume that the humoral response plays a key role in protection against the disease, as previously reported from antibody transfer experiments (24) .
In addition to having outstanding immunogenicity, recombinant VLPs will be of great help in investigating capsid assembly and RNA-packaging processes and in identifying cell membrane structures acting as potential receptors for RHDV.
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